Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.9650
-0.0550 (-5.39%)
Aug 14, 2025, 11:51 AM - Market open
Oncolytics Biotech Employees
Oncolytics Biotech had 28 employees as of December 31, 2024. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change
-1
Growth
-3.45%
Revenue / Employee
n/a
Profits / Employee
-$796,374
Market Cap
102.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ONCY News
- 2 days ago - Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders - PRNewsWire
- 6 days ago - Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep - PRNewsWire
- 6 days ago - Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange - PRNewsWire
- 9 days ago - Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results - PRNewsWire
- 16 days ago - Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - PRNewsWire
- 22 days ago - Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential - PRNewsWire
- 22 days ago - Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules - PRNewsWire
- 4 weeks ago - Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types - PRNewsWire